NCT04956068View on ClinicalTrials.gov

PIPAC for Peritoneal Metastases

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Peritoneal Metastases
Interventions
COMBINATION_PRODUCT

PIPAC

A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.

Trial Locations (1)

169690

RECRUITING

National Cancer Center Singapore, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER

NCT04956068 - PIPAC for Peritoneal Metastases | Biotech Hunter | Biotech Hunter